Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
More Information Supplier PageRuxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
More Information Supplier PageIsotretinoin (13-cis retinoic acid) was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
More Information Supplier PageAcitretin (Etretin, RO 10-1670) is a second generation retinoid used for psoriasis.
More Information Supplier PageBafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit.
More Information Supplier PageDaptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
More Information Supplier PageDoripenem Hydrate (S-4661) is an ultra-broad-spectrum injectable antibiotic, used to treat complicated intra-abdominal infections and complicated urinary tract infections.
More Information Supplier PageDoripenem Hydrate (S-4661) is an ultra-broad-spectrum injectable antibiotic, used to treat complicated intra-abdominal infections and complicated urinary tract infections.
More Information Supplier PageDorzolamide (MK-507, L-671152) HCl is a water-soluble, potent inhibitor of human carbonic anhydrase II and IV with Ki of 1.9 nM and 31 nM, respectively, used as anti-glaucoma agent.
More Information Supplier Page
